These different mechanisms may potentially explain why drugs that reduce the activity of XO, the key enzyme involved in the production of uric acid, but also a significant source of radical oxygen species, failed to change the progression of kidney diseases when used in stage 3 or 4 CKD and provided renal protection when employed in the initial stages of CKD. Here, XDH is linked to chronic kidney disease.